Taoling Zeng

Taoling Zeng

Auto-generated profile, based on publicly available information

Taoling Zeng

State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
QWQingang Wu
Qingang Wu
GLGao Li
Gao Li
CWChengwen Wen
Chengwen Wen
TZTaoling Zeng
Taoling Zeng
YFYuxi Fan
Yuxi Fan
HWHong-Rui Wang
Hong-Rui Wang
Monoubiquitination of p120-catenin controls adherens junction dissociation in TGFβ-induced EMT.

25 July 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
TZTaoling Zeng
Taoling Zeng
TJTingting Jiang
Tingting Jiang
BZBaoding Zhang
Baoding Zhang
TZTing Zhang
Ting Zhang
WDWanjun Dai
Wanjun Dai
HWHong-Rui Wang
Hong-Rui Wang
K-RAS mutations represent a most prevalent oncogenic alteration in human cancers. Despite tremendous efforts, it remains a big challenge to develop strategies that specifically target the oncogenic K-RAS mutants. Here, taking advantage of our previous finding that NEDD4-1 is an E3 ubiquitin ligase for wild-type RAS proteins, we developed a compound XMU-MP-9 that can promote ubiquitination and degradation of various K-RAS mutants including K-RASG12V, and significantly inhibit proliferation and tumor development of K-RAS mutant harboring cells. Mechanistically, XMU-MP-9 acts as a bifunctional compound to bind the C2 domain of NEDD4-1 and an allosteric site of K-RAS to enhance NEDD4-1 and K-RAS interaction, and to induce a conformational change of NEDD4-1/K-RAS complex to allow NEDD4-1 targeting K128 of K-RAS for ubiquitination. Hence, our study presents an effective way to degrade K-RAS mutants to prevent tumor development.

29 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
TZTaoling Zeng
Taoling Zeng
TJTingting Jiang
Tingting Jiang
BZBaoding Zhang
Baoding Zhang
TZTing Zhang
Ting Zhang
WDWanjun Dai
Wanjun Dai
HWHong-Rui Wang
Hong-Rui Wang
K-Ras mutations represent a most prevalent oncogenic alteration in human cancers. Despite of tremendous efforts, it remains a big challenge to develop inhibitors that can target the oncogenic K-Ras mutants, especially mutants without specific active or charged side chains such as K-Ras G12V . Here, taking advantage of our previous finding that Nedd4-1 is a bona fide E3 ubiquitin ligase for wild-type Ras proteins, we developed a compound XMU-MP-9 that can promote ubiquitination and degradation of various K-Ras mutants including K-Ras G12V , and significantly inhibit proliferation and tumor development of K-Ras mutant harboring cells. Mechanistically, XMU-MP-9 acts as a bifunctional compound to bind the C2 domain of Nedd4-1 and an allosteric site of K-Ras to enhance Nedd4-1 and K-Ras interaction, and to induce a conformational change of Nedd4-1/K-Ras complex to allow Nedd4-1 targeting K128 of K-Ras for ubiquitination. Hence, our study presents a robust strategy to develop small-molecule degrader of K-Ras mutants, and also sheds light on the development of small-molecule degraders for H-Ras and N-Ras mutants.